Beren Therapeutics is a biotechnology company developing modified cyclodextrins for diseases involving disrupted cholesterol movement inside cells. Its lead program, adrabetadex, is an investigational drug for Niemann-Pick disease type C (NPC). As of October 8, 2026, Beren reported that the FDA had accepted its application for Priority Review, with a target action date of November 17, 2026; the company also states that the drug has not been approved.
What is Beren Therapeutics working on?
Beren Therapeutics P.B.C. describes itself as a patient-aligned public benefit corporation founded in 2020. Its stated purpose is to discover, develop and deliver pharmaceutical therapies intended to provide optimal benefit for patients. The company says it focuses on cyclodextrin-based medicines for conditions involving impaired cholesterol trafficking, including NPC and other neurodegenerative diseases.
A public benefit corporation is a corporate form that formally includes a public-benefit purpose alongside business objectives. That designation describes Beren’s stated organizational purpose; it does not establish that a candidate medicine is effective, approved or available to patients.
How does Beren’s scientific approach work?
Cholesterol has to move between different parts of a cell to be used or eliminated. Beren’s scientific rationale is that defects in this intracellular transport can leave cholesterol accumulated in some compartments and insufficient in others. The company says this imbalance may contribute to metabolic stress, cellular dysfunction, injury and cell death.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware match#1 Best Overall
Beren is developing derivatized cyclodextrins—modified cyclic oligosaccharides—with the aim of moving accumulated cholesterol for cellular use or elimination. This is the company’s proposed mechanism and platform rationale, not proof that the approach restores health in patients. Beren identifies NPC as its first program.
What is adrabetadex?
Adrabetadex is Beren’s lead investigational candidate for NPC, developed by its subsidiary Mandos LLC. The company describes it as a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers. Beren’s materials discuss administration into the cerebrospinal fluid; the publication index it maintains includes work on administration and clinical studies, but an index alone does not establish a treatment’s benefits or risks.
Rank #2
How does Niemann-Pick disease type C affect cholesterol?
NPC is a rare, autosomal-recessive neurodegenerative disorder associated with pathogenic variants in NPC1 or NPC2 and impaired intracellular cholesterol trafficking. In its August 2026 announcement, Beren said about 95% of cases involve NPC1. The company also reported that earlier neurological onset is associated with faster progression and a poorer prognosis.
Beren’s August 2026 announcement gave mean ages at death of approximately 5.6 years for early-infantile-onset NPC and 13.4 years for late-infantile onset. These are figures reported by the company for those onset groups, not a prediction for an individual or a figure that applies uniformly to every person with NPC.
Is adrabetadex approved?
No. Beren states that adrabetadex has not been approved by the FDA or any other health authority. In an August 2026 announcement, the company said the FDA had accepted the drug’s new drug application for Priority Review and assigned a November 17, 2026 target action date. That is a company-reported target, not a guaranteed decision date or evidence of approval. The status stated here is as of October 8, 2026.
Priority Review describes the FDA review designation reported by Beren; it does not mean the agency has concluded that the drug is safe or effective. Adrabetadex should therefore be described as investigational, not as an approved or commercially available treatment.
What safety information has Beren reported?
Beren’s August 2026 announcement lists hearing impairment, post-dose fatigue and/or ataxia among the main adverse events associated with adrabetadex. The company says hearing impairment may be managed with hearing aids when needed. These are company-reported safety details; they are not individualized medical advice or a complete assessment of the drug’s safety.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What clinical evidence is available in Beren’s materials?
Beren Medical Affairs lists publications concerning clinical studies, expanded access, NPC clinical severity scoring, biomarkers and administration. Examples in its index include a December 2025 paper on 24(S)-hydroxycholesterol as a proximal biomarker during long-term intrathecal adrabetadex therapy, work published in March 2025 on cerebrospinal-fluid total tau, and a 2017 Lancet phase 1–2 study of intrathecal 2-hydroxypropyl-β-cyclodextrin.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Best Value
The index identifies publication titles and venues; it is not a substitute for the underlying studies. Those citations alone do not establish adrabetadex’s efficacy or superiority over another treatment. The company-reported regulatory milestone likewise does not, by itself, establish clinical benefit.
What does Beren’s Test for NPC include?
In September 2026, Beren announced Test for NPC, which it described as combining disease education, NPC GenomeComplete testing, genetic counseling and expert diagnostic support. The company said the initiative is intended to help children receive earlier and accurate diagnoses. Its public announcement, as summarized here, does not establish eligibility, pricing or other program terms.
What else has Beren said about its development program?
In its August 2026 announcement, Beren reported that it held more than 30 issued U.S. patents and that patent protection extended through 2046, subject to possible patent-term extensions, adjustments and supplementary protection certificates. These are company-reported intellectual-property figures; patent protection is distinct from regulatory approval and evidence of a medicine’s clinical benefit.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →
